Vertex and crispr therapeutics announce authorization of the first crispr/cas9 gene-edited therapy, casgevy™ (exagamglogene autotemcel), by the united kingdom mhra for the treatment of sickle cell disease and transfusion-dependent beta thalassemia

Boston & zug, switzerland--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) and crispr therapeutics (nasdaq: crsp) announced today that the united kingdom (u.k.) medicines and healthcare products regulatory agency (mhra) has granted conditional marketing authorization for casgevy™ (exagamglogene autotemcel [exa-cel]), a crispr/cas9 gene-edited therapy, for the treatment of sickle cell disease (scd) and transfusion-dependent beta thalassemia (tdt). casgevy has been authorized.
VRTX Ratings Summary
VRTX Quant Ranking